Patrick Yang Net Worth

The estimated Net Worth of Patrick Y Yang is at least $6.38 million dollars as of 15 March 2022. Patrick Yang owns over 8,000 units of Codexis stock worth over $116,058 and over the last 11 years he sold CDXS stock worth over $6,102,013. In addition, he makes $159,989 as Independent Director at Codexis.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Patrick Yang CDXS stock SEC Form 4 insiders trading

Patrick has made over 23 trades of the Codexis stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 8,000 units of CDXS stock worth $134,320 on 15 March 2022.

The largest trade he's ever made was buying 300,000 units of Codexis stock on 18 May 2017 worth over $87,000. On average, Patrick trades about 20,905 units every 66 days since 2014. As of 15 March 2022 he still owns at least 42,512 units of Codexis stock.

You can see the complete history of Patrick Yang stock trades at the bottom of the page.

Patrick Yang biography

Dr. Patrick Y. Yang serves as Independent Director of the Company. Dr. Yang brings to our board of directors significant experience in pharmaceutical manufacturing and process development. From September 2017 to January 2019, Dr. Yang served as Executive Vice President of Juno Therapeutics, Inc., a biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. From January 2010 to March 2013, Dr. Yang served as Head of Global Technical Operations for F. Hoffmann-La Roche Ltd., where he was responsible for the company’s pharmaceutical and biotechnology manufacturing operations, process development, quality, regulatory, supply management and distribution functions. From December 2003 to December 2009, Dr. Yang worked for Genentech, where he most recently served as Executive Vice President of Product Operations, and was responsible for Genentech’s manufacturing, process development, quality, regulatory affairs and distribution functions. Prior to joining Genentech, Dr. Yang worked for Merck, where he held several leadership roles including Vice President of Asia/Pacific Manufacturing Operations and Vice President of Supply Chain Management. He also previously worked at General Electric Co. and Life Systems, Inc. Dr. Yang currently serves on the board of directors of Tesoro Corporation, a public independent petroleum refining and marketing company, PharmaEssentia Corporation (Taiwan), a public clinical-stage biotechnology company, Amyris, Inc., a public synthetic biology/biotechnology company, and Taiwania Capital Management Company in Taiwan. Dr. Yang earned a B.S. in Engineering from the National Chiaotung University in Taiwan, a M.S. in Electrical Engineering from the University of Cincinnati and a Ph.D. in engineering from the Ohio State University.

What is the salary of Patrick Yang?

As the Independent Director of Codexis, the total compensation of Patrick Yang at Codexis is $159,989. There are 8 executives at Codexis getting paid more, with John Nicols having the highest compensation of $3,408,030.

How old is Patrick Yang?

Patrick Yang is 72, he's been the Independent Director of Codexis since 2014. There are 4 older and 8 younger executives at Codexis. The oldest executive at Codexis Inc. is Thomas Baruch, 81, who is the Independent Director.

What's Patrick Yang's mailing address?

Patrick's mailing address filed with the SEC is C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY, CA, 94063.

Insiders trading at Codexis

Over the last 14 years, insiders at Codexis have traded over $34,923,852 worth of Codexis stock and bought 399,963 units worth $1,488,111 . The most active insiders traders include Ventures Vii, Llc Vivo Vent..., Ventures Life Sciences 2000... et John J Nicols. On average, Codexis executives and independent directors trade stock every 32 days with the average trade being worth of $153,997. The most recent stock trade was executed by Byron L Dorgan on 15 November 2023, trading 20,000 units of CDXS stock currently worth $42,200.

What does Codexis do?

codexis, inc. is a leading protein engineering company applying innovative technologies to unlock the power of proteins™. our proprietary codeevolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. codexis’ revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. you get precisely the protein you need for the job you want it to do. guided by proprietary artificial intelligence software and advanced high-throughput screening systems, codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. since 2002, codexis’ in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough develop

Complete history of Patrick Yang stock trades at Amyris Inc et Codexis

Codexis executives and stock owners

Codexis executives and other stock owners filed with the SEC include:

• John Nicols,
  President, Chief Executive Officer, Director
• John J. Nicols,
  Pres, CEO & Director
• Ross Taylor Jr., M.B.A.,
  Sr. VP & CFO
• Ross Taylor,
  Chief Financial Officer, Senior Vice President
• Bernard Kelley,
  Independent Chairman of the Board
• Byron Dorgan,
  Independent Director
• Pam Cheng,
  Independent Director
• David Smith,
  Independent Director
• Patrick Yang,
  Independent Director
• Dennis Wolf,
  Independent Director
• Thomas Baruch,
  Independent Director
• Jennifer Aaker,
  Independent Director
• Karen Frechou-Armijo,
  Sr. VP & Head of HR
• Asli Aras Ph.D.,
  VP of Corp. Devel.
• Dr. Davinder Singh Brar,
  Special Advisor to the Board
• Prof. Gerhard N. Mayr,
  Special Advisor to the Board
• Robert Sato M.B.A., Ph.D.,
  Sr. VP of Pharmaceutical Devel., Quality & Regulatory
• Dr. Stefan Lutz Ph.D.,
  Sr. VP of Research
• Rob Wilson Ph.D.,
  Sr. VP & GM of Performance Enzymes
• Dr. Gjalt Huisman Ph.D.,
  Sr. VP of Strategic Devel. & GM of Biotherapeutics
• Dr. Karl A. Schoene Ph.D.,
  Sr. VP of Devel. & Operations
• Kathleen Sereda Glaub,
  Director
• Gordon Sangster,
  SVP & Chief Financial Officer
• James Lalonde,
  SVP, R&D
• Ventures Vii, Llc Vivo Vent...,
  
• Douglas T. Sheehy,
  SVP, Gen Counsel and Sec.
• Sriram Ryali,
  Chief Financial Officer
• Ventures Fund Vii, L.P.Vivo...,
  
• David D O'toole,
  SVP & Chief Financial Officer
• Alexander Karsner,
  Director
• Matthew Tobin,
  SVP, Research & Development
• David L. Anton,
  SVP, Research and Development
• Ventures Life Sciences 2000...,
  
• James R Sulat,
  Director
• Mun Yew Wong,
  Director
• Brazil Holding B.V. Shell,
  10% owner
• Bruce A Pasternack,
  Director
• Robert J Lawson,
  SVP and CFO
• Brian Paul Dowd,
  Interim CFO
• Inc Maxygen,
  10% owner
• Peter M Strumph,
  Interim President and CEO
• Joseph J. Sarret,
  CBO, President Pharmaceuticals
• Peter Seufer Wasserthal,
  SVP, Pharmaceuticals
• Enterprises Llc Royal Dutch...,
  
• Alan Shaw,
  President and CEO
• Enterprises Llc Equilon,
  10% owner
• Participacoes Ltda.Royal Du...,
  
• Sciences Investment Fund Pt...,
  
• Esther Martinborough,
  
• H Stewart Parker,
  
• Rahul Singhvi,
  
• Alison Moore,
  
• Margaret Nell Fitzgerald,
  See Remarks
• Stephen George Dilly,
  See Remarks
• Kevin Norrett,
  Chief Operating Officer